Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports

Chiara Zanetta; Massimo Filippi; Lucia Moiola

doi:10.1007/s10072-021-05270-7

Related publications

Article2021

Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients

Giacomo Sferruzza, Ferdinando Clarelli, Elisabetta Mascia, Laura Ferrè, Linda Ottoboni, Melissa Sorosina, Silvia Santoro, Lucia Moiola, Vittorio Martinelli, Gıancarlo Comı, Filippo Martinelli Boneschi, Massimo Filippi, Paolo Provero, Federica Esposito

Article2022

Transcriptional Effects of Fingolimod Treatment on Peripheral T Cells in Relapsing Remitting Multiple Sclerosis Patients

Giacomo Sferruzza, Ferdinando Clarelli, Elisabetta Mascia, Laura Ferrè, Linda Ottoboni, Melissa Sorosina, Silvia Santoro, Massimo Filippi, Paolo Provero, Federica Esposito

Article2022

Early use of fingolimod is associated with better clinical outcomes in relapsing–remitting multiple sclerosis patients

Miryam Cannizzaro, Laura Ferrè, Ferdinando Clarelli, Antonino Giordano, Francesca Sangalli, Bruno Colombo, Gıancarlo Comı, Lucia Moiola, Vittorio Martinelli, Massimo Filippi, Federica Esposito

Article2020

Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis

Laura Ferrè, Andrea Mogavero, Ferdinando Clarelli, Lucia Moiola, Francesca Sangalli, Bruno Colombo, Vittorio Martinelli, Gıancarlo Comı, Massimo Filippi, Federica Esposito

Article2020

Effects of Fingolimod and Natalizumab on Slowly Expanding Lesion Occurrence over Two Years of Treatment in Relapsing-remitting Multiple Sclerosis (1317)

Paolo Preziosa, Elisabetta Pagani, Lucia Moiola, Mariaemma Rodegher, Massimo Filippi, Maria A. Rocca